Analysts expect ImmunityBio, Inc. to report revenue of 61.80 M for Q3 26, against a range of 58.67 M to 64.93 M. The most recent reported quarter, Q2 26, came in at 51.24 M, a 7.1% beat against the 47.83 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 6.11 M | 7.55 M | 16.52 M | 26.43 M | 32.06 M | 38.28 M | 44.21 M | 51.24 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 3.26 M | 9.50 M | 16.22 M | 26.16 M | 33.05 M | 41.18 M | 44.74 M | 51.53 M | 64.93 M | 73.53 M | 74.68 M | 81.31 M | 132.44 M | 176.55 M | 182.95 M | 192.52 M | ||||||||||
| Low Estimate | 2.71 M | 8.47 M | 14.26 M | 22.39 M | 29.23 M | 37.29 M | 38.14 M | 44.12 M | 58.67 M | 61.45 M | 62.05 M | 67.38 M | 118.76 M | 161.89 M | 166.95 M | 161.21 M | ||||||||||
| Consensus Estimate | 2.99 M | 8.99 M | 15.24 M | 24.28 M | 31.14 M | 39.23 M | 41.44 M | 47.83 M | 61.80 M | 67.49 M | 68.37 M | 74.34 M | 125.60 M | 169.22 M | 174.95 M | 176.86 M |
Analysts expect ImmunityBio, Inc. to report earnings per share of -0.07 for Q3 26, against a range of -0.07 to -0.07. The most recent reported quarter, Q2 26, came in at -0.22, a 175.0% miss against the -0.08 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.14 | -0.09 | -0.15 | -0.10 | -0.07 | -0.06 | -0.62 | -0.22 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.15 | -0.18 | -0.13 | -0.11 | -0.10 | -0.08 | -0.07 | -0.08 | -0.07 | -0.06 | -0.09 | -0.09 | 0.05 | 0.08 | -0.03 | 0.06 | ||||||||||
| Low Estimate | -0.19 | -0.20 | -0.15 | -0.13 | -0.12 | -0.08 | -0.07 | -0.08 | -0.07 | -0.08 | -0.09 | -0.09 | 0.05 | 0.06 | -0.03 | 0.06 | ||||||||||
| Consensus Estimate | -0.17 | -0.19 | -0.14 | -0.12 | -0.11 | -0.08 | -0.07 | -0.08 | -0.07 | -0.07 | -0.09 | -0.09 | 0.05 | 0.07 | -0.03 | 0.06 |
Pull Wall Street consensus for ImmunityBio, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=IBRX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "IBRX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=IBRX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();